-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Au8g0PGnZaNLAOzlbsp6W6DiYEByXnXhjXBzX/FD3LGpo6IUjNWZ6imPEAxvzPAW WXEqEGa4RcvCbiqLnRp8rw== 0001218816-04-000002.txt : 20040402 0001218816-04-000002.hdr.sgml : 20040402 20040402093407 ACCESSION NUMBER: 0001218816-04-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040331 FILED AS OF DATE: 20040402 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAPLAN CARL E CENTRAL INDEX KEY: 0001218816 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 04711430 MAIL ADDRESS: STREET 1: C/O FULBRIGHT & JAWORSKI LLP STREET 2: 666 FIFTH AVE CITY: NEW YORK STATE: NY ZIP: 10103 4 1 edgar.xml PRIMARY DOCUMENT X0201 4 2004-03-31 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001218816 KAPLAN CARL E C/O FULBRIGHT & JAWORSKI LLP 666 FIFTH AVENUE NEW YORK NY 10103 1 0 0 0 Common stock, $.01 par value per share 2004-03-31 4 A 0 652 3.83 A 10940 D Options to purchase common stock, $.01 par value pe share 3.83 2004-03-31 4 A 0 5000 3.83 A 2005-03-31 2014-03-31 Common stock, $.01 par value per share 5000 87500 D These shares were granted pursuant to the Company's Stock Compensation Plan for Outside Directors, which provides for the grant to non-employee directors of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter equal to $2,500, until he is no longer an Outside Director. On March 31, 2004, the fair market value of the Common Stock, based on the closing price, was $3.83. These options will become fully vested and immediately exercisable on 03/31/2005. Carl Kaplan 2004-04-02 -----END PRIVACY-ENHANCED MESSAGE-----